Literature DB >> 26981942

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Michael Fischereder1, Ulf Schönermarck1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26981942     DOI： 10.1056/NEJMc1600827

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.

Authors:  Andrew McGovern; Michael Feher; Neil Munro; Simon de Lusignan
Journal:  Diabetes Ther       Date:  2017-03-21       Impact factor: 2.945

Review 2.  Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.

Authors:  Yun-Jing Zhang; Shi-Liang Han; Xi-Feng Sun; Shu-Xiang Wang; Hong-Yun Wang; Xiao Liu; Li Chen; Ling Xia
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

3.  Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus.

Authors:  Jung-Chi Hsu; Chih-Yuan Wang; Mao-Yuan M Su; Lian-Yu Lin; Wei-Shiung Yang
Journal:  Sci Rep       Date:  2019-10-25       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.